Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07254715 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Itopride on Semaglutide Gastroparesis

StatusCompleted
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary completion date changed from estimate of Apr 2026 to Jul 30, 2026 · Start date changed from estimate of Dec 2025 to Jan 1, 2026 · Eligibility criteria expanded, about 12 words · 1 more Show 4 more changesShow less
    • Primary completion date changed from estimate of Apr 2026 to Jul 30, 2026
    • Start date changed from estimate of Dec 2025 to Jan 1, 2026
    • Eligibility criteria expanded, about 12 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery. The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before anesthesia.
Trial Details
NCT Number NCT07254715
Lead Sponsor Ain Shams University
Conditions Semaglutide-Induced Gastric Motility, Anesthesia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov